These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 25591543)
21. Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era. Juliano RL; Astriab-Fisher A; Falke D Mol Interv; 2001 Apr; 1(1):40-53. PubMed ID: 14993337 [TBL] [Abstract][Full Text] [Related]
22. Pharmaceutical implications of helix length control in helix-mediated protein-protein interactions. Milroy LG; Brunsveld L Future Med Chem; 2013 Dec; 5(18):2175-83. PubMed ID: 24261893 [TBL] [Abstract][Full Text] [Related]
23. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. Ran X; Gestwicki JE Curr Opin Chem Biol; 2018 Jun; 44():75-86. PubMed ID: 29908451 [TBL] [Abstract][Full Text] [Related]
24. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Verdine GL; Walensky LD Clin Cancer Res; 2007 Dec; 13(24):7264-70. PubMed ID: 18094406 [TBL] [Abstract][Full Text] [Related]
25. Peptide therapeutics: current status and future directions. Fosgerau K; Hoffmann T Drug Discov Today; 2015 Jan; 20(1):122-8. PubMed ID: 25450771 [TBL] [Abstract][Full Text] [Related]
30. A study of 2-component i, i + 3 peptide stapling using thioethers. St Louis LE; Rodriguez TM; Waters ML Bioorg Med Chem; 2018 Mar; 26(6):1203-1205. PubMed ID: 29122441 [TBL] [Abstract][Full Text] [Related]
32. Computer-aided design of amino acid-based therapeutics: a review. Farhadi T; Hashemian SM Drug Des Devel Ther; 2018; 12():1239-1254. PubMed ID: 29795978 [TBL] [Abstract][Full Text] [Related]
33. Peptides and peptide conjugates: therapeutics on the upward path. Ahrens VM; Bellmann-Sickert K; Beck-Sickinger AG Future Med Chem; 2012 Aug; 4(12):1567-86. PubMed ID: 22917246 [TBL] [Abstract][Full Text] [Related]
34. Building on Success: A Bright Future for Peptide Therapeutics. Angell Y; Holford M; Moos WH Protein Pept Lett; 2018; 25(12):1044-1050. PubMed ID: 30430932 [TBL] [Abstract][Full Text] [Related]
35. Stabilized helical peptides: overview of the technologies and its impact on drug discovery. Klein M Expert Opin Drug Discov; 2017 Nov; 12(11):1117-1125. PubMed ID: 28889766 [TBL] [Abstract][Full Text] [Related]
36. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. Hewitt WM; Leung SS; Pye CR; Ponkey AR; Bednarek M; Jacobson MP; Lokey RS J Am Chem Soc; 2015 Jan; 137(2):715-21. PubMed ID: 25517352 [TBL] [Abstract][Full Text] [Related]
37. Computational methods-guided design of modulators targeting protein-protein interactions (PPIs). Qiu Y; Li X; He X; Pu J; Zhang J; Lu S Eur J Med Chem; 2020 Dec; 207():112764. PubMed ID: 32871340 [TBL] [Abstract][Full Text] [Related]
38. Venoms as a platform for human drugs: translating toxins into therapeutics. King GF Expert Opin Biol Ther; 2011 Nov; 11(11):1469-84. PubMed ID: 21939428 [TBL] [Abstract][Full Text] [Related]
39. Emerging strategies to access peptide macrocycles from genetically encoded polypeptides. Smith JM; Frost JR; Fasan R J Org Chem; 2013 Apr; 78(8):3525-31. PubMed ID: 23517465 [TBL] [Abstract][Full Text] [Related]
40. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Watt PM Nat Biotechnol; 2006 Feb; 24(2):177-83. PubMed ID: 16465163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]